Back to GEODE CAPITAL MANAGEMENT, LLC GEODE CAPITAL MANAGEMENT, LLC

BCLIBCLI
4 quarters

Position history for GEODE CAPITAL MANAGEMENT, LLCGEODE CAPITAL MANAGEMENT, LLC's holdings in BrainStorm Cell Therapeutics In

No. Geode Capital Management exited its BCLI (BrainStorm Cell Therapeutics in) position in Q3 2025. Its Q2 2025 13F listed 54,582 shares worth $61,143. Geode Capital Management first reported BCLI in Q4 2024 and held it in 3 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$119,206

Total Shares Change

-52,501

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q3
Latest
Exited
0
-100.0%
$00.0%$0.70
0
2025-Q2
Decreased
54,582
-6.2%
$61,1430.0%$1.06
0
2025-Q1
Increased
58,165
+10.8%
$73,3030.0%$1.19
16
2024-Q4
New
52,501
-
$119,2060.0%$2.37
34

Other major holders of BCLI: VANGUARD GROUP INC, BlackRock, Inc., HRT FINANCIAL LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used